NEW YORK (GenomeWeb) – Toronto-based ChipCare is developing a microfluidic diagnostic platform that works similarly to a flow cytometer, but will be made available at a fraction of the cost and size.
The firm, a 2009 spinout from the University of Toronto, expects to make available a rugged, hand held system at the point of patient care, and expects to have a CE-marked HIV-related diagnostic test on the market in Africa around the end of 2017.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
